Clinical Trials Logo

Hepatitis, Autoimmune clinical trials

View clinical trials related to Hepatitis, Autoimmune.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04790916 Terminated - Clinical trials for Autoimmune Hepatitis

Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)

Start date: April 19, 2021
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the effect of RO7049665 on time to relapse following forced corticosteroid (CCS) tapering as measured by the hazard ratio between RO7049665 7.5 milligrams (mg) and placebo arm.

NCT ID: NCT04339621 Terminated - Clinical trials for Autoimmune Hepatitis

AIH Risk Stratification With Multiparametric MRI

Start date: October 20, 2020
Phase:
Study type: Observational

The primary aim of this study is to investigate whether the baseline cT1 can predict those whose condition relapses following treatment withdrawal. The secondary aim is to investigate correlation of cT1 with histology to explore utility as a monitoring tool. A total of 97 patients with AIH will be recruited and divided into 2 arms. 20 of which will be treatment naive and the other 77 will have been on treatment for the past 18-24 months and will be coming in for therapy cessation review.

NCT ID: NCT04203875 Terminated - Clinical trials for Autoimmune Hepatitis

Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis

Start date: March 9, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate whether Orencia® (Abatacept) improves outcomes in liver transplant patients with recurrent or de novo AIH (autoimmune hepatitis) that has not responded to previous therapy. AIH that does not respond to steroids or conventional immunotherapy often affects young patients and leads to irreversible liver damage. There is currently no effective therapy for this condition.

NCT ID: NCT04129489 Terminated - Clinical trials for Autoimmune Hepatitis

A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis

Start date: February 7, 2019
Phase: Phase 2
Study type: Interventional

Subjects with stable autoimmune hepatitis disease currently being administered corticosteroids with or without azathioprine (AZA) treatment will be be treated with Cannabidiol instead of standard of care treatment with corticosteroids

NCT ID: NCT02056054 Terminated - Clinical trials for De Novo Autoimmune Hepatitis

De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation

Start date: September 9, 2013
Phase:
Study type: Observational

The purpose of this study is to provide insights into the cause, development and effects of de novo autoimmune hepatitis so that prevention and treatment strategies can be developed in order to reduce post-liver transplant morbidity, the frequency of liver allograft loss and the need for re-transplantation.

NCT ID: NCT00608894 Terminated - Clinical trials for Autoimmune Hepatitis

LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

Start date: December 2007
Phase: Phase 2
Study type: Interventional

An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs. azathioprine, each in combination with prednisone, for the treatment of autoimmune hepatitis (AIH).

NCT ID: NCT00286663 Terminated - Clinical trials for Hepatitis, Autoimmune

Autoimmune Hepatitis Study

Start date: January 2006
Phase: Phase 1
Study type: Observational

The purpose of the study is to determine the role special antibodies play in possibly identifying Autoimmune Hepatitis through the following: Identify the response of specific T cells to antibodies and Monitor the response of the cells that regulate the immune system